Evidaxia

JCA Pulse › Ongoing JCA

Ongoing JCA

Camizestrant: EU joint clinical assessment

Treatment of adults with locally advanced or metastatic breast cancer

  1. Regulatory review
  2. CHMP opinion
  3. EU authorised
  4. JCA report published

Overview

Company
AstraZeneca
Therapy area
Solid tumours · Breast
Indication
Treatment of adults with locally advanced or metastatic breast cancer
Product type
Chemical
EMA validation
19 Jun 2025
JCA assessor
Federation of Social Insurances, Austria
Co-assessor
National Institute for Health and Disability, Belgium
Regulatory status
EU marketing authorisation 20 Jul 2026 (Etcamah), with a CDK4/6i on ESR1 mutation detection without progression on 1L ET + CDK4/6i. JCA report listed as ongoing at 15 Oct 2026.
Latest
EU-authorised 20 Jul 2026; JCA report still pending; European price talks ongoing.
Pivotal evidence
SERENA-6 (phase 3, RCT)
01

Scope

The PICO forecast

JCA Pulse forecasts 1–2 PICOs for Camizestrant, with 2 candidate comparators. See the populations, comparators and likely outcomes the assessment is set to cover.

Unlock the PICO forecastFree with email
02

Evidence

Fit against the likely scope

Camizestrant’s pivotal evidence (SERENA-6) is randomised. Pro scores how well it fits each likely PICO and flags where assessors may push back.

Included in Pro
03

Comparisons

Trials and indirect comparisons

Pro maps every trial likely in the Camizestrant dossier and projects the indirect comparison each comparator will need.

Included in Pro
04

Countries

National translator and outlook

Austria and Belgium lead the joint assessment. Pro explains what the JCA means for the national route in each of 31 markets, with 3 national records already in place.

See JCA Pulse ProIncluded in Pro

Sources

Last checked 5 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.

From Evidaxia

Also in Solid tumours